English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met. Data as of 01/11/2026.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 240.00%
Price change 2019 → 2020: -26.47%
Price change 2020 → 2021: 16.00%
Price change 2021 → 2022: -57.24%
Price change 2022 → 2023: -33.87%
Price change 2023 → 2024: 85.85%
Price change 2024 → 2025: 15.75%
Price change 2025 → 2026: 35.60%
Price change 2026 (year to date): 26.43%
Financial growth
Revenue CAGR (8 years): 11.51%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.23
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -40.00
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 23.92% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="CMPD" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| CompuMed, Inc. | – | 0.23 | +10.2 % | 🔒 |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| Femasys Inc. | – | 0.80 | +16.2 % | – |
| Spineway S.A. | – | 0.07 | +9.3 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by CompuMed, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 5.3 m | 338,436 | 6.4 % | n/a |
| 2021 | 6.3 m | 1.1 m | 16.9 % | +19.9 % |
| 2022 | 6.4 m | 501,851 | 7.9 % | +0.8 % |
| 2023 | 5.8 m | -32,604 | -0.6 % | -8.3 % |
| 2024 | 6.2 m | 192,659 | 3.1 % | +6.6 % |
| 2025 | 7.5 m | -64,227 | -0.8 % | +21.3 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by CompuMed, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 2.2 m | 1.8 m | 1.1 m | 1.6 m | 1.7 m |
| Total Debt | 764,979 | 538,460 | 392,975 | 522,523 | 713,589 |
| Net Debt | -1.4 m | -1.3 m | -686,231 | -1.0 m | -940,501 |
| Equity | 3.4 m | 3.8 m | 3.1 m | 3.3 m | 3.1 m |
| Total assets | 5.1 m | 5.3 m | 4.4 m | 4.6 m | 5.0 m |
| Operating cash flow | 1.4 m | 735,585 | 520,476 | 877,343 | 1.2 m |
| Investments (capex) | 881,931 | 908,846 | 370,376 | 522,309 | 1.2 m |
| Free cash-flow | 537,480 | -173,261 | 150,100 | 355,030 | 19,930 |
| Share buybacks | 0 | 13,945 | 724,336 | 0 | 130,695 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about CompuMed, Inc.
What is the CompuMed, Inc. share price?
Latest recorded price: 5.53 USD on 06/11/2026, for a market cap of 7.1 m USD.
What is the revenue of CompuMed, Inc.?
7.5 m USD for fiscal year 2025, with net income of -64,227 USD (net margin -0.8 %).
Is CompuMed, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US2049145012).
How many employees does CompuMed, Inc. have?
8 full-time employees according to the latest published profile.
Who runs CompuMed, Inc.?
Lee Keddie is the company's chief executive.